ArticleOncotarget2018

A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.

Cesar August Santa-Maria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.